Johana Sottile

Johana Sottile

Auto-generated profile, based on publicly available information

Johana Sottile

Research Laboratory, Hospital General Universitario de Alicante-Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2018 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
AGAraceli García-Martínez
Araceli García-Martínez
JSJohana Sottile
Johana Sottile
LSLaura Sánchez-Tejada
Laura Sánchez-Tejada
CFCarmen Fajardo
Carmen Fajardo
RCRosa Cámara
Rosa Cámara
APAntonio M. Picó
Antonio M. Picó
Context Epigenetic alterations may play a role in the development and behaviour of Pituitary Neuroendocrine Tumours (PitNETs). Objective To evaluate the effect of methylation of Tumour Suppressor Genes (TSGs) in their gene expression and in the behaviour of PitNETs. Material and Methods We use MS-MLPA and q-RT-PCR techniques to analyse the DNA-promoter hypermethylation and the gene expression of 35 TSGs in 105 PitNETs. We define functionality, size and invasiveness of tumours according to their clinical manifestations, Hardy’s classification and MRI invasion of the cavernous sinus, respectively. Results We observed different methylation patterns among PitNET subtypes. CASP8 was the most hypermethylated gene in all PitNET subtypes. The methylation status of TP73 correlated negatively with their gene expression in the overall series (p=0.013) and in some subtypes. MSH6 and CADM1 showed higher methylation frequency in macro than in microadenomas in the overall series and in corticotroph PitNETs (all p≤0.053). ESR1 and RASSF1 were higher methylated in non-invasive than in invasive tumours in the overall series (p=0.054 and p=0.031, respectively) and in the gonadotroph subtype (sGT) (p=0.055 and p=0.050, respectively). ESR1 and CASP8 appeared more hypermethylated in functioning than in sCT (p=0.034 and p=0.034, respectively). Conclusions DNA-methylation of TSGs has a selective effect on their gene expression and on the growth and invasiveness of PitNETs. Its involvement in their functionality is biased because all silent operated tumours are macroadenomas while all operated microadenomas are functioning ones. Therefore, the subtypes of PitNETs should be considered as different entities.

6 July 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAraceli García-Martínez
Araceli García-Martínez
JSJohana Sottile
Johana Sottile
CFCarmen Fajardo
Carmen Fajardo
PRPedro Riesgo
Pedro Riesgo
RCRosa Cámara
Rosa Cámara
APAntonio M. Picó
Antonio M. Picó
The aim of the present study is to check whether we can replicate, in an independent series, previous results showing that the molecular study of pituitary-specific gene expression complements the inmunohistochemical identification of pituitary neuroendocrine tumours. We selected 112 patients (51 (46.4%) women; mean age 51.4±16 years; 102 macroadenomas (91.9%), 9 microadenomas (8.1%)) with complete clinical, radiological, immunohistochemical and molecular data from our data set of pituitary neuroendocrine tumours. Patients were different from those previously studied. We measured the expression of the pituitary-specific hormone genes and type 1 corticotrophin-releasing hormone and arginine vasopressin 1b receptors, by quantitative real-time polymerase chain reaction using TaqMan probes. Afterwards, we identified the different pituitary neuroendocrine tumour subtypes following the 2017 World Health Organization classification of pituitary tumours, calculating the concordance between their molecular and immuhistochemical identification. The concordance between molecular and immunohistochemical identification of functioning pituitary neuroendocrine tumours with the clinical diagnosis was globally similar to the previous series, where the SYBR Green technique was used instead of TaqMan probes. Our results also corroborated the poor correlation between molecular and immunohistochemical detection of the silent pituitary neuroendocrine tumour variants. This discrepancy was more remarkable in lactotroph, null-cell and plurihormonal pituitary neuroendocrine tumours. In conclusion, this study validates the results previously published by our group, highlighting a complementary role for the molecular study of the pituitary-specific hormone genes in the typification of pituitary neuroendocrine tumours subtypes.